Pfizer Vaccine Effective Against Delta in South African Study
(Bloomberg) -- The Pfizer Inc.-BioNTech SE Covid-19 vaccine helps prevent severe disease among those infected with the delta variant, according to research involving 1.2 million medical insurance plan members in South Africa.
The study provides large-scale evidence that the Pfizer shot works against this dominant variant, according to Ryan Noach, the chief executive officer of Discovery Health Ltd., Africa's biggest health insurer. The data used was gathered from the start of the country's mass vaccination campaign on May 17 through Sept. 23.
“This research was performed during a period when the delta variant was highly prevalent in South Africa,” he said in a briefing Thursday. “The vaccine effectiveness during a delta wave has not been widely reported on in large global studies, making this research even more relevant.”
While South Africa has set a target to inoculate 70% of the adult population by December, based on current levels it's estimated that only about 50% will be vaccinated by year end, he said. This points to some vaccine hesitancy in the country, which has sufficient shots, even after struggling to procure enough earlier in the year.
Two weeks after the first dose, the Pfizer vaccine is 73% effective in protecting against hospital admission, according to the study. Waiting the same period after the second shot raises that to 92%. For those that have had Covid-19 and followed the two-dose regimen, there is a 98% drop in the risk of hospital admission related to the coronavirus.
Unvaccinated members had a five times higher risk of infection and 20 times the risk of dying from complications of a Covid-19 infection, the data showed. No vaccine-related deaths were recorded among Discovery Health members.
An earlier trial involving almost 480,000 health workers in South Africa who got the Johnson & Johnson vaccine also showed that that shot worked in preventing severe disease among those infected with the delta variant.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.